Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The Antidepressant Effect of Ketamine Is Dampened by Concomitant Benzodiazepine Medication

V. Andrashko, T. Novak, M. Brunovsky, M. Klirova, P. Sos, J. Horacek,

. 2020 ; 11 (-) : 844. [pub] 20200828

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21002100

The rapid antidepressant effect of ketamine has become a breakthrough in the research and treatment of depression. Although predictive and modulating factors of the response to ketamine are broadly studied, little is known about optimal concurrent medication protocols. Concerning gamma-aminobutyric acid neurotransmission being a shared target for both ketamine and benzodiazepines (BZD), we evaluated the influence of BZD on the antidepressant effect of a single ketamine infusion in depressed patients. Data from 47 patients (27 females) with major depression (MADRS ≥ 20, ≥ 1 prior nonresponse to antidepressant treatment in current episode) who participated in two previous studies (EudraCT Number: 2009-010625-39 and 2013-000952-17) entered the analysis. All of the subjects were given an infusion of a subanesthetic dose of racemic ketamine (0.54 mg per kg) as an add-on medication to ongoing antidepressant treatment. Thirteen patients (28%) reached ≥ 50% reduction in MADRS within one week after ketamine administration. Nineteen (40%) patients took concomitant benzodiazepines on a daily basis. The doses of BZDs were significantly higher in nonresponders (p=0.007). ROC analysis distinguished responders from nonresponders by a criterion of >8mg of diazepam equivalent dose (DZ equivalent) with a sensitivity of 80% and a specificity of 85% (p<0.001). RM-ANOVA revealed a different time pattern of response to ketamine between the BZD+ (>8mg of DZ equivalent) and BZD- (≤8mg of DZ equivalent) groups, with a significantly worse outcome in BZD+ on day 3 (p=0.04) and day 7 (p=0.02). The results of the study indicate that concomitant benzodiazepine treatment in higher doses may attenuate ketamine's antidepressant effect. The pathophysiological, clinical and methodological implications of this finding should be considered in future research and ketamine treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21002100
003      
CZ-PrNML
005      
20210126092652.0
007      
ta
008      
210105s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3389/fpsyt.2020.00844 $2 doi
035    __
$a (PubMed)33005153
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Andrashko, Veronika $u Clinical Research of Mental Disorders, National Institute of Mental Health, Klecany, Czechia. Third Faculty of Medicine, Charles University, Prague, Czechia.
245    14
$a The Antidepressant Effect of Ketamine Is Dampened by Concomitant Benzodiazepine Medication. / $c V. Andrashko, T. Novak, M. Brunovsky, M. Klirova, P. Sos, J. Horacek,
520    9_
$a The rapid antidepressant effect of ketamine has become a breakthrough in the research and treatment of depression. Although predictive and modulating factors of the response to ketamine are broadly studied, little is known about optimal concurrent medication protocols. Concerning gamma-aminobutyric acid neurotransmission being a shared target for both ketamine and benzodiazepines (BZD), we evaluated the influence of BZD on the antidepressant effect of a single ketamine infusion in depressed patients. Data from 47 patients (27 females) with major depression (MADRS ≥ 20, ≥ 1 prior nonresponse to antidepressant treatment in current episode) who participated in two previous studies (EudraCT Number: 2009-010625-39 and 2013-000952-17) entered the analysis. All of the subjects were given an infusion of a subanesthetic dose of racemic ketamine (0.54 mg per kg) as an add-on medication to ongoing antidepressant treatment. Thirteen patients (28%) reached ≥ 50% reduction in MADRS within one week after ketamine administration. Nineteen (40%) patients took concomitant benzodiazepines on a daily basis. The doses of BZDs were significantly higher in nonresponders (p=0.007). ROC analysis distinguished responders from nonresponders by a criterion of >8mg of diazepam equivalent dose (DZ equivalent) with a sensitivity of 80% and a specificity of 85% (p<0.001). RM-ANOVA revealed a different time pattern of response to ketamine between the BZD+ (>8mg of DZ equivalent) and BZD- (≤8mg of DZ equivalent) groups, with a significantly worse outcome in BZD+ on day 3 (p=0.04) and day 7 (p=0.02). The results of the study indicate that concomitant benzodiazepine treatment in higher doses may attenuate ketamine's antidepressant effect. The pathophysiological, clinical and methodological implications of this finding should be considered in future research and ketamine treatment.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Novak, Tomas $u Clinical Research of Mental Disorders, National Institute of Mental Health, Klecany, Czechia. Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Brunovsky, Martin $u Clinical Research of Mental Disorders, National Institute of Mental Health, Klecany, Czechia. Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Klirova, Monika $u Clinical Research of Mental Disorders, National Institute of Mental Health, Klecany, Czechia. Third Faculty of Medicine, Charles University, Prague, Czechia.
700    1_
$a Sos, Peter $u Clinical Research of Mental Disorders, National Institute of Mental Health, Klecany, Czechia.
700    1_
$a Horacek, Jiri $u Clinical Research of Mental Disorders, National Institute of Mental Health, Klecany, Czechia. Third Faculty of Medicine, Charles University, Prague, Czechia.
773    0_
$w MED00174602 $t Frontiers in psychiatry $x 1664-0640 $g Roč. 11, č. - (2020), s. 844
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33005153 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210126092648 $b ABA008
999    __
$a ind $b bmc $g 1614165 $s 1122384
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 11 $c - $d 844 $e 20200828 $i 1664-0640 $m Frontiers in psychiatry $n Front Psychiatry $x MED00174602
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...